JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aguirre, N.
Right arrow Articles by Del Río, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aguirre, N.
Right arrow Articles by Del Río, J.

Vol. 286, Issue 3, 1159-1165, September 1998

The Role of Dopaminergic Systems in the Perinatal Sensitivity to 3,4-Methylenedioxymethamphetamine-Induced Neurotoxicity in Rats1

Norberto Aguirre, Meritxell Barrionuevo, Berta Lasheras and Joaquín Del Río

Department of Pharmacology, University of Navarra, 31008 Pamplona, Spain

Our study was aimed at analyzing the basis for the apparent lack of perinatal sensitivity to the serotonergic neurotoxin 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). MDMA (20 mg/kg s.c.) repeatedly administered to rat dams during gestation, did not affect [3H]paroxetine-labeled serotonin (5-HT) transporter density and 5-HT content in the offspring. A single dose of MDMA was then given to pups, not exposed prenatally to MDMA, at different postnatal ages (PND14, 21, 28 and 35). Long-term significant reductions in 5-HT levels in all the brain regions examined were only found at PND35. In a different set of experiments, MDMA administered at PND21 alone or in combination with (R)-1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane (R-DOI, 0.5 mg/kg s.c.), or L-3,4-dihydroxyphenylalanine (L-DOPA, 80 mg/kg s.c.), caused a significant hyperthermia in the pups. However, only L-DOPA followed by MDMA caused a lasting reduction of 5-HT levels and 5-HT transporter density in the hippocampus and in the frontal cortex. In adult animals, no change in 5-HT levels and 5-HT transporter density in different brain regions was either found when MDMA was given to rats previously lesioned with 6-hydroxydopamine, but a significant reduction was again found in the lesioned animals receiving MDMA in combination with L-DOPA. These results appear to indicate that the hyperthermia induced by MDMA is not sufficient to produce lasting neurotoxic effects on the serotonergic system, at least at PND21, and support an important role for dopamine in the mechanism of neurotoxicity of MDMA, suggesting that an already developed dopaminergic system is necessary for the expression of the serotonergic deficits.


0022-3565/98/2863-1159$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
D. C. Jones, S. S. Lau, and T. J. Monks
Thioether Metabolites of 3,4-Methylenedioxyamphetamine and 3,4-Methylenedioxymethamphetamine Inhibit Human Serotonin Transporter (hSERT) Function and Simultaneously Stimulate Dopamine Uptake into hSERT-Expressing SK-N-MC Cells
J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 298 - 306.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy")
Pharmacol. Rev., September 1, 2003; 55(3): 463 - 508.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
H. W. Broening, L. L. Morford, S. L. Inman-Wood, M. Fukumura, and C. V. Vorhees
3,4-Methylenedioxymethamphetamine (Ecstasy)-Induced Learning and Memory Impairments Depend on the Age of Exposure during Early Development
J. Neurosci., May 1, 2001; 21(9): 3228 - 3235.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.